BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BCRX
  • CUSIP: 09058V10
Key Metrics:
  • Previous Close: $4.10
  • 50 Day Moving Average: $3.81
  • 200 Day Moving Average: $3.10
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.31
  • P/E Growth: -0.20
  • Market Cap: $308.07M
  • Outstanding Shares: 73,700,000
  • Beta: 3.08
Additional Links:
Companies Related to BioCryst Pharmaceuticals:

Analyst Ratings

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.36)
Consensus Price Target: $8.22 (96.70% upside)

Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Show:
DateFirmActionRatingPrice TargetDetails
8/12/2016Piper Jaffray Cos.UpgradeNeutral -> Overweight$5.00 -> $8.00View Rating Details
8/5/2016HC WainwrightReiterated RatingBuyView Rating Details
8/5/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
8/5/2016Jefferies GroupBoost Price TargetHold$2.00 -> $3.00View Rating Details
8/4/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
7/6/2016FBR & CoReiterated RatingBuy$6.00View Rating Details
2/26/2016Noble FinancialReiterated RatingBuy$8.00View Rating Details
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00View Rating Details
2/8/2016Needham & Company LLCDowngradeBuy -> HoldView Rating Details
11/11/2015Bank of America Corp.DowngradeNeutral -> Underperform$12.00 -> $10.00View Rating Details
11/10/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details
8/10/2015MLV & Co.Reiterated RatingBuy$15.00View Rating Details
(Data available from 8/28/2014 forward)

Earnings

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/4/2016Q216($0.26)($0.22)$3.92 million$4.80 millionViewN/AView Earnings Details
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.21)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details
5/8/2014Q114($0.17)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Current Year EPS Consensus Estimate: $-1.01 EPS
Next Year EPS Consensus Estimate: $-0.97 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.24)($0.20)($0.23)
Q2 20165($0.25)($0.17)($0.22)
Q3 20163($0.26)($0.22)($0.24)
Q4 20163($0.26)($0.24)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2016Bros. Advisors Lp BakerMajor ShareholderSell4,046,590$5.00$20,232,950.00View SEC Filing  
8/12/2016Thomas R Staab IIInsiderSell5,864$5.18$30,375.52View SEC Filing  
8/9/2016Thomas R Staab IIInsiderSell14,577$4.43$64,576.11View SEC Filing  
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.75View SEC Filing  
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.00View SEC Filing  
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.65View SEC Filing  
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.00View SEC Filing  
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.00View SEC Filing  
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72View SEC Filing  
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00View SEC Filing  
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00View SEC Filing  
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.85View SEC Filing  
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.00View SEC Filing  
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateHeadline
mysmartrend.com logoAfter Yesterday's Decline of 5.13%, BioCryst Pharmaceuticals Offers Investors Better Value (NASDAQ:BCRX)
www.mysmartrend.com - August 25 at 9:10 PM
News IconBiotech news that matter for investors: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Arrowhead Pharmaceuticals ... - The Voice Registrar (NASDAQ:BCRX)
voiceregistrar.com - August 24 at 12:00 PM
insidermonkey.com logoBiocryst Pharmaceuticals Inc (BCRX): Billionaire David E. Shaw’s Fund Increases Stake (NASDAQ:BCRX)
www.insidermonkey.com - August 23 at 3:50 PM
finance.yahoo.com logoBIOCRYST PHARMACEUTICALS INC Financials (NASDAQ:BCRX)
finance.yahoo.com - August 17 at 3:52 PM
insidermonkey.com logoBiocryst Pharmaceuticals Inc (BCRX): Baker Bros. Advisors Unloads Nearly 4 Million Shares (NASDAQ:BCRX)
www.insidermonkey.com - August 17 at 11:57 AM
News Icon2 Biotech Stocks News And Price Trends: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), ZIOPHARM Oncology, Inc ... - The Voice Registrar (NASDAQ:BCRX)
voiceregistrar.com - August 16 at 3:51 PM
investornewswire.com logoWill BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hit $10 Price Target? - Investor Newswire (NASDAQ:BCRX)
www.investornewswire.com - August 16 at 12:28 PM
News IconStocks to Watch: BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX), First Solar, Inc.(NASDAQ:FSLR) - NYSE Journal (press release) (NASDAQ:BCRX)
stockznews.com - August 15 at 3:53 PM
capitalcube.com logoETF’s with exposure to BioCryst Pharmaceuticals, Inc. : August 15, 2016 (NASDAQ:BCRX)
www.capitalcube.com - August 15 at 11:00 AM
investornewswire.com logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Brokerage Rating Update - Investor Newswire (NASDAQ:BCRX)
www.investornewswire.com - August 12 at 3:58 PM
capitalcube.com logoBioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:BCRX)
www.capitalcube.com - August 12 at 3:58 PM
streetinsider.com logoBioCryst Pharma (BCRX) Does First Patient in BCX7353 APeX-1 Study (NASDAQ:BCRX)
www.streetinsider.com - August 12 at 12:25 PM
finance.yahoo.com logoBioCryst Pharma upgraded by Piper Jaffray (NASDAQ:BCRX)
finance.yahoo.com - August 12 at 12:25 PM
News IconAnalyst's keeping an Eye on: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Post Registrar (NASDAQ:BCRX)
postregistrar.com - August 11 at 9:40 PM
finance.yahoo.com logo10:19 am BioCryst Pharma doses the first subject in the APeX-1 clinical trial of BCX7353 for the oral treatment of hereditary angioedema (NASDAQ:BCRX)
finance.yahoo.com - August 11 at 12:32 PM
biz.yahoo.com logoBIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:BCRX)
biz.yahoo.com - August 11 at 12:32 PM
publicnow.com logoBioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema (NASDAQ:BCRX)
www.publicnow.com - August 11 at 12:32 PM
fool.com logoHere's the Buzz Behind BioCryst Pharmaceuticals, Inc.'s 27% Gain in July (NASDAQ:BCRX)
www.fool.com - August 11 at 12:32 PM
finance.yahoo.com logoBulls pile into Biocryst Pharmaceuticals (NASDAQ:BCRX)
finance.yahoo.com - August 10 at 4:11 PM
seekingalpha.com logoBiocryst Where To From Here? - Seeking Alpha (NASDAQ:BCRX)
seekingalpha.com - August 10 at 7:52 AM
streetupdates.com logoStocks inside Analysts Limelight: Amarin Corporation PLC (NASDAQ:AMRN) , BioCryst Pharmaceuticals, Inc ... - Street Updates (NASDAQ:BCRX)
www.streetupdates.com - August 10 at 7:52 AM
News IconBiggest Movers in Healthcare: MannKind Corp. (NASDAQ:MNKD), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - TWN (NASDAQ:BCRX)
thewellesleysnews.com - August 10 at 7:52 AM
biz.yahoo.com logoBIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:BCRX)
biz.yahoo.com - August 8 at 3:49 PM
finance.yahoo.com logoEdited Transcript of BCRX earnings conference call or presentation 4-Aug-16 3:00pm GMT (NASDAQ:BCRX)
finance.yahoo.com - August 5 at 9:09 PM
fortune.com logoNotable Stock Analyst Ratings: Primoris Services Corp (NASDAQ:PRIM), BioCryst Pharmaceuticals, Inc. (NASDAQ ... - Review Fortune (NASDAQ:BCRX)
reviewfortune.com - August 5 at 3:47 PM
seekingalpha.com logoBioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:BCRX)
seekingalpha.com - August 5 at 3:47 PM
News Icon2 Biotech Stocks News And Price Trends: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), PTC Therapeutics, Inc ... - The Voice Registrar (NASDAQ:BCRX)
voiceregistrar.com - August 4 at 3:53 PM
sg.finance.yahoo.com logoBioCryst reports 2Q loss (NASDAQ:BCRX)
sg.finance.yahoo.com - August 4 at 12:22 PM
marketwatch.com logoWatch these biotechs as the Zika virus moves to the U.S. (NASDAQ:BCRX)
www.marketwatch.com - August 4 at 12:22 PM
equities.com logoBioCryst Pharmaceuticals Inc. (BCRX) Jumps 6.9% on August 03 - Equities.com (NASDAQ:BCRX)
www.equities.com - August 3 at 9:28 PM
ftsenews.co.uk logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Updated Price Targets - FTSE News (NASDAQ:BCRX)
www.ftsenews.co.uk - August 1 at 3:43 PM
News IconHC Stocks Watchful: Sangamo Biosciences, Inc. (NASDAQ:SGMO ... - share market updates (press release) (NASDAQ:BCRX)
sharemarketupdates.com - August 1 at 3:43 PM
investornewswire.com logoWill BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Surprise Analysts? - Investor Newswire (NASDAQ:BCRX)
www.investornewswire.com - July 31 at 3:43 PM
News IconHot Biotech Stocks Recap: BioCryst Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:BCRX)
voiceregistrar.com - July 29 at 3:48 PM
thestreet.com logo8 Stocks Under $10 to Trade for Huge Profits (NASDAQ:BCRX)
www.thestreet.com - July 29 at 6:59 AM
streetupdates.com logoAnalysts Observable Stocks: Exelixis, Inc. (NASDAQ:EXEL) , BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Street Updates (NASDAQ:BCRX)
www.streetupdates.com - July 28 at 12:33 PM
equities.com logoBioCryst Pharmaceuticals Inc. (BCRX) Jumps 13.67% on July 27 - Equities.com (NASDAQ:BCRX)
www.equities.com - July 28 at 12:33 PM
finance.yahoo.com logoBioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 13.7% (NASDAQ:BCRX)
finance.yahoo.com - July 28 at 8:25 AM
investornewswire.com logoCan BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Surprise Analysts this Quarter? - Investor Newswire (NASDAQ:BCRX)
www.investornewswire.com - July 26 at 11:36 AM
investornewswire.com logoCan Shares Of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hit $16? - Investor Newswire (NASDAQ:BCRX)
www.investornewswire.com - July 25 at 9:53 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - TGP (NASDAQ:BCRX)
telanaganapress.com - July 22 at 3:44 PM
finance.yahoo.com logoBioCryst to Announce Second Quarter 2016 Financial Results August 4 (NASDAQ:BCRX)
finance.yahoo.com - July 21 at 7:15 AM
News IconBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:BCRX)
www.engelwooddaily.com - July 20 at 11:50 AM
News IconBiocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) Sellers Increased By 1.14% Their Shorts - Consumer Eagle (NASDAQ:BCRX)
www.consumereagle.com - July 19 at 3:47 PM
investornewswire.com logoIs $16 Price Target Attainable For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)? - Investor Newswire (NASDAQ:BCRX)
www.investornewswire.com - July 19 at 3:47 PM
News IconWere Analysts Bullish BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) This Week? - Consumer Eagle (NASDAQ:BCRX)
www.consumereagle.com - July 17 at 3:41 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Fiscal Standard (NASDAQ:BCRX)
www.fiscalstandard.com - July 17 at 3:41 PM
News IconBiocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) Shorted Shares Decreased By 11.95% - Press Telegraph (NASDAQ:BCRX)
presstelegraph.com - July 16 at 3:46 PM
kcregister.com logoAlliqua Biomedical Inc (NASDAQ:ALQA) went up 4.24%: BioCryst Pharmaceuticals (NASDAQ:BCRX), AK Steel ... - KC Register (NASDAQ:BCRX)
www.kcregister.com - July 16 at 9:43 AM
News IconShares Experiencing a Downtrend: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - TGP (NASDAQ:BCRX)
telanaganapress.com - July 16 at 9:43 AM

Social

BioCryst Pharmaceuticals (NASDAQ:BCRX) Chart for Sunday, August, 28, 2016


Last Updated on 8/28/2016 by MarketBeat.com Staff